

Complement-mediated kidney disease: C3 glomerulopathy and IgA nephropathy

Supplement Editor

Brian F. Mandell, MD, PhD
Rheumatologic and Immunologic Disease
Cleveland Clinic

Table of Contents

e1 C3 glomerulopathy

Ali Mehdi, MD, MEd, FACP, FASN; Jonathan J. Taliercio, DO

e5 IgA nephropathy

Jonathan J. Taliercio, DO; Ali Mehdi, MD, MEd, FACP, FASN

Topics and editors for supplements to the *Cleveland Clinic Journal of Medicine* are determined by the *Journal's* editor-in-chief and staff. Supplement editors are chosen for their expertise in the topics discussed and are responsible for the scientific quality of supplements, including the review process. The *Journal* ensures that supplement editors and authors fully disclose any relationships with industry, including the supplement underwriter.

From the editor

In this supplement, I have invited 2 experienced clinical nephrologists and medical educators to present overviews of C3 glomerulopathy (C3G) and IgA nephropathy. These 2 disorders are strikingly different in their prevalence. IgA nephropathy is the most common primary glomerulonephritis worldwide, while C3G is rare. They share several characteristics. Both require renal biopsy for definitive diagnosis and both have a variable long-term course, although untreated C3G has a generally poorer prognosis. Progression of both can be slowed by manipulation of renal hemodynamics and, to an often unsatisfying degree, by utilizing broadsword immunosuppression with corticosteroids and other agents including mycophenolate mofetil.

The fascinating observation that further unifies these disorders, as discussed by Mehdi and Taliercio, is that they share as a pathophysiologic mechanism the localized activation of complement via its “alternative pathway.” The activation triggers differ in the 2 disorders, but the rapidly growing understanding of this pathway has already led to the implementation of specific therapeutics in clinical trials.

Brian F. Mandell, MD, PhD

Cleveland Clinic Journal of Medicine [ISSN 0891-1150 (print), ISSN 1939-2869 (online)] is published monthly by Cleveland Clinic.

DISCLAIMER: Statements expressed in this supplement to the *Cleveland Clinic Journal of Medicine* are those of the authors and not necessarily of Cleveland Clinic or its Board of Trustees.

SUBSCRIPTIONS: U.S. and possessions: personal \$160 institutional \$188; single copy/back issue \$20. Foreign: \$205 single copy/back issue \$20. Institutional (multiple-reader rate) applies to libraries, schools, hospitals, and federal, commercial, and private institutions

and organizations. Individual subscriptions must be in the names of, billed to, and paid by individuals.

SUBSCRIPTIONS, EDITORIAL, BILLING, AND PRODUCTION:
Cleveland Clinic Journal of Medicine, 9500 Euclid Avenue, JJ44, Cleveland, OH 44195
Phone (216) 444-2661 • Fax (216) 444-9385 • E-mail ccjm@ccf.org • www.ccjm.org

© 2023 THE CLEVELAND CLINIC FOUNDATION. ALL RIGHTS RESERVED. PRINTED IN U.S.A.

